TCGA-K4-A4AB-01B-12R-A28M-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.496714849
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- TNFA_SIGNALING_VIA_NFKB+0.510
- ANGIOGENESIS+0.500
- UV_RESPONSE_DN+0.460
- NOTCH_SIGNALING+0.370
- TGF_BETA_SIGNALING+0.370
- MYOGENESIS+0.360
- APICAL_JUNCTION+0.350
- ESTROGEN_RESPONSE_EARLY+0.350
- INFLAMMATORY_RESPONSE+0.350
Top 10 suppressed
- E2F_TARGETS-0.670
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V2-0.550
- MYC_TARGETS_V1-0.520
- OXIDATIVE_PHOSPHORYLATION-0.380
- DNA_REPAIR-0.300
- MTORC1_SIGNALING-0.270
- INTERFERON_ALPHA_RESPONSE-0.250
- UNFOLDED_PROTEIN_RESPONSE-0.230
- MITOTIC_SPINDLE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0DV-01A-21R-A12P-07 | — | A | 0.943 |
| 2 | 4c7083b3-eccc-4d80-a31d-6fd3cd0222b4 | — | — | 0.928 |
| 3 | TCGA-DQ-5624-01A-01R-1873-07 | — | — | 0.921 |
| 4 | TCGA-BH-A0AZ-01A-21R-A12P-07 | — | A | 0.919 |
| 5 | TCGA-A2-A0EO-01A-11R-A034-07 | — | A | 0.917 |
| 6 | 6b548699-9440-4acc-86b6-faeb367454a2 | — | — | 0.916 |
| 7 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.915 |
| 8 | SRR25617877 | — | A | 0.914 |
| 9 | TCGA-A2-A0ES-01A-11R-A115-07 | — | A | 0.911 |
| 10 | 20030015.LumB | — | A | 0.910 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.370 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |